Nano-vehicles give new lease of life to existing antimicrobials.


Journal

Emerging topics in life sciences
ISSN: 2397-8554
Titre abrégé: Emerg Top Life Sci
Pays: England
ID NLM: 101706399

Informations de publication

Date de publication:
17 12 2020
Historique:
received: 30 09 2020
revised: 06 11 2020
accepted: 09 11 2020
pubmed: 2 12 2020
medline: 18 9 2021
entrez: 1 12 2020
Statut: ppublish

Résumé

Antibiotic resistance has become one of the greatest challenges for modern medicine, and new approaches for the treatment of bacterial infections are urgently needed to avoid widespread vulnerability again to infections that have so far been easily treatable with existing drugs. Among the many approaches investigated to overcome this challenge is the use of engineered nanostructures for the precise and targeted delivery of existing antimicrobial agents in a fashion that will potentiate their effect. This idea leans on lessons learned from pioneering research in cancer, where the targeted delivery of anti-cancer drugs to mammalian cells has been a topic for some time. In particular, new research has demonstrated that nanomaterials can be functionalised with active antimicrobials and, in some cases, with targeting molecules that potentiate the efficiency of the antimicrobials. In this mini-review, we summarise results that demonstrate the potential for nanoparticles, dendrimers and DNA nanostructures for use in antimicrobial delivery. We consider material aspects of the delivery vehicles and ways in which they can be functionalised with antibiotics and antimicrobial peptides, and we review evidence for their efficacy to kill bacteria both in vitro and in vivo. We also discuss the advantages and limitations of these materials and highlight the benefits of DNA nanostructures specifically for their versatile potential in the present context.

Identifiants

pubmed: 33258900
pii: 227096
doi: 10.1042/ETLS20200153
pmc: PMC7752037
doi:

Substances chimiques

Anti-Bacterial Agents 0
Anti-Infective Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

555-566

Subventions

Organisme : Wellcome Trust
ID : 089703/Z/ 09/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 3-3249/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K015850/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K02292X/1
Pays : United Kingdom

Informations de copyright

© 2020 The Author(s).

Auteurs

Ioanna Mela (I)

Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, U.K.

Clemens F Kaminski (CF)

Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, U.K.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH